Galectin-3: A New Biomarker for Atherosclerosis Management

Akın, Yeşim; Demirkan, Burcu; Suljevic, Senay Akin; İpek, Esra Gücük

doi:10.1177/0003319720941763

Cited by 1 publication

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Galectin-3 is now recognized as both a cardiovascular inflammatory biomarker and a mediator of atherosclerosis [ 11 ]. It induces the expression of various pro-inflammatory mediators in human macrophages [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

“…It induces the expression of various pro-inflammatory mediators in human macrophages [ 24 ]. Furthermore, Galectin-3 contributes to atherosclerosis by engaging in processes like lipid uptake, vascular smooth muscle cell proliferation and migration, and endothelial dysfunction [ 11 , 12 , 25 , 26 ]. Oyenuga et al .…”

Section: Discussionmentioning

confidence: 99%

“…Galectin-3 is a ubiquitously expressed

-galactoside-binding protein of the lectin family that regulates various cellular functions, such as cell-cell and cell-matrix interactions, proliferation, and differentiation [ 7 ]. Moreover, it contributes to the development of inflammation and tissue fibrosis [ 7 , 8 ], and of conditions such as heart failure [ 9 ], atherosclerosis [ 10 , 11 ], and cardiovascular diseases [ 12 ]. Human specimens showed increased galectin-3 levels in atherosclerotic carotid and lower limb arteries when compared to umbilical cord arteries [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

“…Human specimens showed increased galectin-3 levels in atherosclerotic carotid and lower limb arteries when compared to umbilical cord arteries [ 10 ]. Galectin-3 is considered a potential cardiovascular inflammatory biomarker [ 11 ]. According to the Atherosclerosis Risk in Communities (ARIC) study, an independent association was observed between galectin-3 and the development of incident PAD and critical limb ischemia in the general population [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

High Serum Galectin-3 Level as a Potential Biomarker of Peripheral Artery Disease in Patients Undergoing Hemodialysis

Chiu,

Hsu,

Lai

et al. 2024

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

Background: Galectin-3 is implicated in the pathogenesis of inflammation and atherosclerosis. Peripheral arterial disease (PAD), characterized by a reduced ankle-brachial index (ABI), is a prognostic marker for mortality in patients on hemodialysis. We investigated the relationship between serum galectin-3 levels and PAD in patients undergoing regular hemodialysis. Methods: We carried out a cross-sectional study at a medical center, involving 92 participants. Serum galectin-3 levels were assessed by a commercially available enzyme-linked immunosorbent assay. ABI measurement was done with an automatic device based on oscillometry. Participants were categorized into two groups, normal and low ABI, based on a 0.9 cut-off point. Results: Eighteen patients (19.6%) exhibited a low ABI. In individuals with low ABIs, we observed a greater prevalence of diabetes mellitus, elevated serum C-reactive protein (CRP) levels, increased galectin-3 levels, and lower serum creatinine levels. Furthermore, serum galectin-3 levels (odds ratio [OR]: 1.056, 95% confidence interval [CI]: 1.003–1.112, p = 0.037) and CRP (per 0.1 mg/dL increment, OR: 1.195, 95% CI: 1.032–1.383, p = 0.017) were identified as independent predictors of PAD. Serum galectin-3 and log-transformed CRP levels were also independently and significantly negatively correlated with the left and right ABI values. Conclusions: Serum galectin-3 levels correlate with PAD in patients undergoing maintenance hemodialysis.

show abstract

Section: Discussionmentioning

confidence: 99%